New Risk Management Provisions in EU Pharmacovigilance
In the ever-evolving world of pharmacovigilance, the EU is constantly seeking to strike a delicate balance between ensuring patient safety and fostering innovation. With their recent update to pharmacovigilance legislation which came into effect in July 2023. The spotlight falls on generics and biosimilars, raising important questions about risk management. Let's dive into the new provisions and explore what they mean for these critical players in the pharmaceutical landscape.